Literature DB >> 26985302

MALT1 Inhibitors May Potentially Treat Lymphomas and Autoimmune Disorders.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2016        PMID： 26985302      PMCID： PMC4789668          DOI： 10.1021/acsmedchemlett.6b00015

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

Review 1.  Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment.

Authors:  Shaun Rosebeck; Peter C Lucas; Linda M McAllister-Lucas
Journal:  Future Oncol       Date:  2011-05       Impact factor: 3.404

Review 2.  Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.

Authors:  Lorena Fontán; Ari Melnick
Journal:  Clin Cancer Res       Date:  2013-09-04       Impact factor: 12.531

Review 3.  Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspase.

Authors:  Stephan Hailfinger; Georg Lenz; Margot Thome
Journal:  Curr Opin Chem Biol       Date:  2014-10-04       Impact factor: 8.822
  3 in total
  1 in total

1.  Secondary Metabolites from the Fungus Dictyosporium sp. and Their MALT1 Inhibitory Activities.

Authors:  Trong D Tran; Brice A P Wilson; Curtis J Henrich; Louis M Staudt; Lauren R H Krumpe; Emily A Smith; Jarrod King; Karen L Wendt; Alberto M Stchigel; Andrew N Miller; Robert H Cichewicz; Barry R O'Keefe; Kirk R Gustafson
Journal:  J Nat Prod       Date:  2019-01-02       Impact factor: 4.050
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.